ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
R&D outsourcing trends roundtable
Solomon Babani, SVP and General Partner, Biotech and Small/Mid-Size Pharma, contributes to this article on today’s R&D outsourcing trends across drug development, clinical trial services and manufacturing.
Biomarkers give clinical trials of neurodegenerative diseases a head start
Dr. Peter Schueler explores how biomarkers that detect the molecular changes preceding the clinical symptoms of neurodegenerative disease, are critical for clinical trials at pre-symptomatic stages.
The changing pace of vaccines: How COVID-19 has impacted the future of infectious disease vaccine development
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development of future vaccines.
Panel discussion: setting the roadmap for optimising cancer clinical trials
In this podcast, Martin Lachs discusses how clinical trials have been the backbone of cancer research.
The changing face of cell and gene therapy: impacts on planning and executing trials
In this webinar, Brandon Fletcher and Martin Lachs review some of the factors investigational teams should now consider in the planning and execution of cell and gene therapy development programs.
Contract research is having a moment right now. Will M&A splashes drive the industry to even greater heights?
ICON CEO, Dr. Steve Cutler, offers his perspective of the ever- changing CRO landscape based on recent mergers and acquisitions in the industry. (Subscription required to read)
Navigating the patient maze – pharma’s evolving challenge
Chris O'Toole considers the challenges that pharma companies may face when adopting a more patient-centric approach.
Irish clinical trials company ICON gets €4m state funding
This article reports on ICON’s multimillion-euro funding from the Irish government to enhance its decentralised and hybrid trial capabilities.
Irish clinical trials company ICON gets €4m State funding for R&D
ICON has received €4m in R&D investment from the Irish government to further develop its technology for decentralised and hybrid clinical trials.
Connections, collaboration key to executing global trials
Leon Dzivinsky share his insights on navigating borders, cultures, regulatory issues and other important considerations on worldwide studies.